title: Evolution of IGF-1 in children born small for gestational age and with growth retardation, treated by growth hormone adapted to IGF-1 levels after 1 year.
abstract: OBJECTIVE
  This study was designed to estimate the percentage of growth hormone (GH)-treated children born small for gestational age (SGA), with serum IGF-1 >2 SDS before and after GH dose adaptation.
  
  
  METHODS
  SGA boys aged 4-9 and girls aged 4-7 with a height <-2 SDS and an annual growth rate below the mean received a subcutaneous GH dose of 57 μg/kg/day for 2 years. The GH dose was to be decreased by 30% in children with serum IGF-1 >2 SDS at 12 months and on the previous sample. The GH dose could be reduced a second time to 35 μg/kg·day. IGF-1 and IGFBP-3 dosages were centralized.
  
  
  RESULTS
  Among the 49 (21 boys) children included in the study, 8 (16.3%) had an IGF-1 >2 SDS consecutively at 9 and 12 months (95% CI 7.3, 29.7). The GH dose was decreased in 6/8 children. However, IGF-1 levels were elevated at several nonconsecutive determinations in 45% (95% CI 28.4, 56.6) of the patients.
  
  
  CONCLUSIONS
  A high IGF-1 level is observed in 45% of the GH SGA-treated children with a relatively high dose of GH. A 30% reduction in the GH dose causes a decrease in IGF-1 below 2 SDS in most children.
authors.affiliation: Department of Paediatric Endocrinology, APHP, Hôpital Armand-Trousseau, Centre de Référence Maladies Endocriniennes Rares de la Croissance (CRMERC) and Research Unit 938 Inserm-UPMC Paris VI, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Cabrol
authors.forename: L
authors.initials: L
authors.lastname: Perin
authors.forename: M
authors.initials: M
authors.lastname: Colle
authors.forename: R
authors.initials: R
authors.lastname: Coutant
authors.forename: M
authors.initials: M
authors.lastname: Jésuran-Perelroizen
authors.forename: Y
authors.initials: Y
authors.lastname: Le Bouc
authors.forename: P
authors.initials: P
authors.lastname: Czernichow
mesh_terms: D000465:Algorithms; D001827:Body Height / Q000187:drug effects; D002648:Child; D002657:Child Development / Q000187:drug effects*; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D004351:Drug Resistance; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood* / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I